Decaline based HMC-COA reductase inhibitors with two C-6 substituents
US5210228A · kind A · utility
3Cited by
6References
6Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 16, 1991 |
| Grant date | May 11, 1993 |
| Priority date | — |
| Expiry date | Sep 16, 2011 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07C69/732
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
Compounds of either of general formulae I and II: ##STR1## wherein: R.sup.1, R.sup.2, R.sup.3, R.sup.5, R.sup.6, a, b, c, and d are variables. These compounds are useful in the treatment of hypercholesterolaemia in general and arteriosclerosis, familial hypercholesterolaemia or hyperlipidaemia in particular.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.